Key result
Transitioning to inactivated polio vaccine (IPV) avoids the very low risk of vaccine-associated paralytic poliomyelitis (one case per 2.5 million doses) while maintaining immunity against polio.
Transitioning from OPV to IPV is necessary for total polio eradication and prevents vaccine-associated paralytic poliomyelitis.
No takes yet. Share an insight, caveat, or question.
Supports IPV transition to avert VAPP; leaves open optimal eradication strategies in endemic regions.
Wood et al. (2003) conducted a review in Poliomyelitis. Inactivated polio vaccine (IPV) vs. Oral polio vaccine (OPV) was evaluated. Transitioning to inactivated polio vaccine (IPV) avoids the very low risk of vaccine-associated paralytic poliomyelitis (one case per 2.5 million doses) while maintaining immunity against polio.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: